Rchr
J-GLOBAL ID：201801008028014995
Update date: Aug. 25, 2024
Kondo Tsunenori
コンドウ ツネノリ | Kondo Tsunenori
Affiliation and department：
Job title：
Professor
Research field (1)：
Urology
Research keywords (3)：
外科的治療
, 腫瘍免疫学
, 泌尿器科悪性腫瘍
Research theme for competitive and other funds (2)：
- 2024 - 2027 性ホルモンによる免疫チェックポイント阻害剤治療効果への臨床的影響とその機序の解明
- 泌尿器科腫瘍、腫瘍免疫学
Papers (198)：
-
Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, et al. Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Targeted oncology. 2024. 19. 4. 623-633
-
Hiroki Ishihara, Nemoto Yuki, Ryo Ishiyama, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, et al. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. Japanese journal of clinical oncology. 2024. 54. 5. 577-583
-
Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, et al. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. International journal of clinical oncology. 2024
-
Hiroki Ishihara, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yoji Nagashima, Tsunenori Kondo, Toshio Takagi. Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. International journal of urology : official journal of the Japanese Urological Association. 2023
-
Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi. Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. Japanese journal of clinical oncology. 2023
ｍore...
Return to Previous Page
